| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
81.33(B) |
| Last
Volume: |
9,792,067 |
Avg
Vol: |
8,697,344 |
| 52
Week Range: |
$63.43 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,000 |
25,472 |
36,973 |
80,792 |
| Total Sell Value |
$145,920 |
$2,022,270 |
$2,937,849 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
1 |
5 |
8 |
14 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Oday Daniel Patrick |
Chairman & CEO |
• • – |
2022-06-10 |
4 |
D |
$60.74 |
$93,479 |
D/D |
(1,539) |
251,105 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2022-06-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,300 |
252,644 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2022-06-10 |
4 |
D |
$60.74 |
$119,597 |
D/D |
(1,969) |
67,056 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2022-06-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,672 |
69,025 |
|
- |
|
| Rodriguez Javier |
Director |
• • – |
2022-05-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,223 |
4,061 |
|
- |
|
| Bluestone Jeffrey |
Director |
• • – |
2022-05-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,223 |
3,264 |
|
- |
|
| Manwani Harish |
Director |
• • – |
2022-05-03 |
4 |
D |
$60.33 |
$21,055 |
D/D |
(349) |
7,528 |
|
- |
|
| Manwani Harish |
Director |
• • – |
2022-05-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,223 |
7,877 |
|
- |
|
| Lofton Kevin E |
Director |
• • – |
2022-05-03 |
4 |
OE |
$0.00 |
$0 |
I/I |
2,223 |
92,748 |
|
- |
|
| Barton Jacqueline K |
Director |
• • – |
2022-05-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,223 |
17,899 |
|
- |
|
| Horning Sandra |
Director |
• • – |
2022-05-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,112 |
1,744 |
|
- |
|
| Welters Anthony |
Director |
• • – |
2022-05-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,223 |
3,591 |
|
- |
|
| Lofton Kevin E |
Director |
• • – |
2022-04-28 |
4 |
OE |
$25.63 |
$418,251 |
I/I |
16,322 |
90,525 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2022-03-11 |
4 |
S |
$58.24 |
$211,644 |
D/D |
(3,634) |
32,576 |
|
-5% |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2022-03-10 |
4 |
D |
$57.92 |
$208,628 |
D/D |
(3,602) |
64,005 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,901 |
67,607 |
|
- |
|
| Wilfong Diane E |
SVP, Controller & CAO |
• • – |
2022-03-10 |
4 |
D |
$57.92 |
$54,155 |
D/D |
(935) |
26,581 |
|
- |
|
| Wilfong Diane E |
SVP, Controller & CAO |
• • – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,297 |
27,516 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2022-03-10 |
4 |
D |
$57.92 |
$120,995 |
D/D |
(2,089) |
36,210 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,723 |
38,299 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2022-03-10 |
4 |
D |
$57.92 |
$203,010 |
D/D |
(3,505) |
41,265 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,612 |
44,770 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2022-03-10 |
4 |
D |
$57.92 |
$186,560 |
D/D |
(3,221) |
34,544 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,987 |
37,765 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2022-03-10 |
4 |
D |
$57.92 |
$640,132 |
D/D |
(11,052) |
249,344 |
|
- |
|
2511 Records found
|
|
Page 8 of 101 |
|
|
1.50 (2.36%) 
